PORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:
|
|
|
- Leslie Nelson
- 5 years ago
- Views:
Transcription
1 May 2016 Randomisation Checklist Form 1, page 1 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : Please contact the IKNL Clinical Trial Centre in case of questions regarding eligibility or problems with the randomisation procedure: , Mo to Fri 09:00 17:00 h. trialbureau@iknl.nl or portec@iknl.nl STRATIFICATION: Histological grade (1=grade 1, 2=grade 2, 3=grade 3)... Type of surgery (1=TAH-BSO or TLH-BSO without lymphadenectomy, 2= TAH-BSO or TLH-BSO with lymphadenectomy)... INCLUSION CRITERIA: (0=no, 1=yes) Histologically confirmed endometrioid type endometrial carcinoma, FIGO 2009 staging, with one of the following combinations of substage, age and grade... 1 = Stage IA (with invasion), grade 3 (any age, with or without LVSI) 2 = Stage IB, grade 1 or grade 2, age 60 years 3 = Stage IB, grade 1 or grade 2 with documented LVSI 4 = Stage IB, grade 3 without LVSI 5 = Stage II, grade 1 Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral Salpingo-Oophorectomy (TH-BSO) with or without lymphadenectomy... WHO performance status 0, 1 or 2... Written informed consent... Date written informed consent... Informed consent also for storage of remaining tissue for translational research... EXCLUSION CRITERIA: (0=no, 1=yes) Any other stage of endometrial carcinoma... Histological types serous or clear cell carcinoma (for mixed tumors, > 10% serous or clear cell type)... Uterine sarcoma (incl.carcinosarcoma)... History of previous malignancy within the last 5 years, except for non-melanomatous skin cancer... Previous pelvic radiotherapy... Interval between date of surgery and start of brachytherapy > 8 weeks... Date: Investigator s signature:
2 May 2016 Randomisation Checklist Form 1, page 2 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : Please contact the IKNL Clinical Trial Centre in case of questions regarding eligibility or problems with the randomisation procedure: , Mo to Fri 09:00 17:00 h. trialbureau@iknl.nl or portec@iknl.nl PATHOLOGY: Original Pathology Lab... Original Pathology Number... Has regional review PA been done and is the tumour tissue still at this pathology lab?(0=no, 1=yes)... If yes, regional review Pathology Lab... If yes, regional review Pathology Number... INFORMATION GIVEN AT RANDOMIZATION: Date of randomisation... Patient study number... Treatment allocation... 1= Standard treatment recommendation based on clinicopathological factors 2= Individual treatment recommendation based on molecular pathology Please do not forget to send in the pre-treatment Quality of life questionnaire and address form! CONTACT INFORMATION RANDOMISING PHYSICIAN/RESEARCH NURSE: Name and function... Telephone number... address... Investigators signature...
3 May 2016 On study form Form 2, page 1 of 3 PATIENT CHARACTERISTICS: WHO performance Status (0-4)... Patient height (cm)... Patient weight (kg)... Presence of diabetes, treated with medication (0=no, 1=yes, 9=unknown)... Presence of hypertension, treated with medication (0=no, 1=yes, 9=unknown)... Previous or present history of cardiovascular disease (0=no, 1=yes, specify, 9=unknown)... Specify cardiovascular disease... Menopausal status (1=pre menopausal, 2=post menopausal, 9=unknown)... (please note; post menopausal: at least 1 year after last menstruation) Vaginal atrophy at pelvic exam (0 = no atrophy 1 = slight atrophic changes, 2 = moderate atrophy with teleangiectasia, 3 = marked atrophy with stenosis/shortening 4 = ulceration or necrosis, 9 = unknown)... INVESTIGATIONS: Chest Radiograph or chest CT (0= normal and no metastases, 1=benign abnormalities, no metastases, 2 = other or uncertain, specify below, 3=not done)... Specify... Pre-operative CT or MRI scan (abdomen and pelvis) done (0=no, 1=yes)... If yes, CT or MRI scan findings (0 = normal, 1 = enlarged uterus, no other abnormalities, 2 = iliac and/or para-aortic lymphadenopathy*, 3 = other or combination*, 4 = not done)... * specify:... Post-operative CT or MRI scan (abdomen and pelvis) done (0=no, 1=yes)... If yes, CT or MRI scan findings (0 = normal, 1= post surgery changes, no suspect abnormalities, 2 = para-aortic lymphadenopathy*, 3 = signs of residual tumor*, 4 = other or combination*, 5 = not done)... * specify:...
4 May 2016 On study form Form 2, page 2 of 3 SURGERY: Date of surgery... Type of surgery (1=TAH-BSO, 2=TAH-BSO + lymphadenectomy, 3= Laparoscopic TLH-BSO or LAVH-BSO, 4= Laparoscopic TLH-BSO or LAVH-BSO + lymphadenectomy)... If laparoscopic surgery, conversion to abdominal surgery (0=no, 1=yes)... Other biopsies or excision of suspected tumour deposits (0=no, 1=yes, specify)... Specify location... Complications of surgery (0=no, 1 = wound dehiscence, 2 = wound infection, 3 = bowel obstruction, 4 = other*, 5 = combination*;)... Specify complications... Re-operation for complications (0=no, 1=yes)... If yes, date of re-operation... PATHOLOGY (ORIGINAL): Histologic classification (1 = endometrioid adenocarcinoma, 2= mixed endometrioid and serous or clear cell (<10% of serous or clear cell component), 3 = mucinous type endometrial cancer, 4=squamous type endometrial cancer, 5=other type, specify )... Specify other type of endometrial cancer... FIGO Histologic grade (1 = G1, 2= G2, 3 = G3)... Size of the tumour (maximal diameter in mm)... Myometrial invasion (1 = <50%, 2 = > 50%)... Minimal distance between the tumor and the serosa at the point of the deepest myometrial invasion (mm).... Growth through serosa (0=no, 1=yes)... Cervical stromal involvement (0=no, 1=yes)... Involvement of the ovaries or tubes * (0=no, 1=yes, ovary, 2=yes, tube)... * Other than tubal corner of endometrial cavity Lymph-vascular space invasion (LVSI) (0=no, 1=yes)... Parametrial involvement (0=no, 1=yes, 2=not stated or unknown)... Single or limited lymph node biopsy * (0=not done, 1=no malignancy, 2=metastasis)... Pelvic staging lymphadenectomy * (0=not done, 1=no malignancy, 2=metastasis)... * If done, number of nodes examined...
5 May 2016 On study form Form 2, page 3 of 3 * If done, number of nodes with tumour involvement... Para-aortic lymph node biopsy * (0=not done, 1=no malignancy, 2=metastasis)... * If done, number of nodes examined... * If done, number of nodes with tumour involvement... Other biopsies* (0=not done, 1=no malignancy, 2=metastasis, specify)... Specify location metastasis... FIGO 2009 stage (1 = IA, 2= IB, 3=II)... PLEASE DO NOT FORGET TO UPLOAD A COPY OF THE ORIGINAL PATHOLOGY REPORT IN TRIAS Date:.. Investigator s signature:.
6 May 2016 Treatment form Form 3, page 1 of 3 TREATMENT GIVEN: Brachytherapy (0=no, 1=yes)... External Beam Radiotherapy (0=no, 1=yes)... Observation (0=no, 1=yes)... Was there a deviation from allocated treatment? (0=no, 1=yes, patient refusal, specify below, 2= yes, other, specify below)... Specify refusal or other reason for no treatment... BRACHYTHERAPY: First day of brachytherapy... Last day of brachytherapy... Applicator type (1=vaginal cylinder, 2=other, please specify type and give reason)... Specify type and reason for other applicator type... Vaginal cylinder diameter (mm)... Active source length (mm)... Reference volume length (mm)... Reference volume width (mm)... Dose rate (1 = High Dose Rate (HDR), 2 = Pulsed Dose Rate (PDR), used as HDR)... Total dose (at prescription isodose, 100% (Gy)).... Dose per fraction (at prescription isodose, 100% (Gy)).... Interval between fraction number 1 and number 2 (days)... Interval between fraction number 2 and number 3 (days)... Number of fractions... Dose to 2-cc of the rectum fraction 1 (Gy).... Dose to 2-cc of the rectum fraction 2 (Gy).... Dose to 2-cc of the rectum fraction 3 (Gy).... Dose to 2-cc of the bladder fraction 1 (Gy).... Dose to 2-cc of the bladder fraction 2 (Gy).... Dose to 2-cc of the bladder fraction 3 (Gy).... Dose to 2-cc of the sigmoid fraction 1 (Gy).... Dose to 2-cc of the sigmoid fraction 2 (Gy)....
7 May 2016 Treatment form Form 3, page 2 of 3 Dose to 2-cc of the sigmoid fraction 3 (Gy).... Dose to 2-cc of the small bowel fraction 1 (Gy).... Dose to 2-cc of the small bowel fraction 2 (Gy).... Dose to 2-cc of the small bowel fraction 3 (Gy).... Dose to 90% of the CTV fraction 1(Gy).... Dose to 90% of the CTV fraction 2(Gy).... Dose to 90% of the CTV fraction 3(Gy).... Dose to 98% of the CTV fraction 1(Gy).... Dose to 98% of the CTV fraction 2(Gy).... Dose to 98% of the CTV fraction 3(Gy).... Was the brachytherapy treatment interrupted 7 days or discontinued (0=no, 1= interrupted 7 days, 2= discontinued)... If interrupted or discontinued, please specify reason (1= refusal, 2= brachytherapy toxicity, 3=surgical complications, 4=unrelated cause)... Specify reason... Were there any toxicities during brachytherapy (0=no, 1=yes, fill out CRF 5)... External Beam RT (EBRT): First day of EBRT... Last day of EBRT... EBRT technique (1=IMRT or volumetric arc therapy, 2=3D conformation radiotherapy, 3=tomotherapy, 4=other, specify)... Specify other EBRT technique... Target volume (1=pelvic area to S1 or L5, 2=pelvic and lower para-aortic area to L4 or L3, 3= pelvic and lower para-aortic area to L2 or L1) Total dose at prescription point (Gy).... Dose per fraction at prescription point (Gy).... Number of fractions... Total dose at prescription point (Gy).... Minimal dose to 95% of the PTV (Gy).... Maximal dose PTV (Gy)....
8 May 2016 Treatment form Form 3, page 3 of 3 Was the EBRT treatment interrupted 3 days or discontinued (0=no, 1= interrupted 3 days, 2= discontinued)... If interrupted or discontinued, please specify reason (1= refusal, 2= radiotherapy toxicity, 3=other complications, 4=unrelated morbidity)... Specify reason and given dose at interruption... Were there any toxicities during EBRT (0=no, 1=yes, fill out CRF 5)... Date:.. Investigator s signature:.
9 May 2016 End Of Treatment form Form 4, page 1 of 1 TREATMENT DISCONTINUATION: Date end of treatment (date evaluation last treatment phase)... Major reason for treatment discontinuation... 0 = normal treatment completion or allocated to observation 1 = disease progression / death due to progressive disease 2 = toxicity 3 = patient refusal (not related to toxicity) 4 = intercurrent death (not due to endometrial carcinoma or treatment) 5 = other, please specify... SURVIVAL STATUS: Date last known to be alive or date of death... Survival status (0=alive, 1=dead)... If dead, main cause... 1 = Disease progression 2 = Treatment complications (primary treatment), please specify... 3 = Cardiovascular disease 4 = Infection, not due to protocol treatment 5 = Other intercurrent death, not due to endometrial carcinoma... In case of death or major toxicity, date SAE form sent... Date:.. Investigator s signature:.
10 May 2017 Toxicity form Form 5, page 1 of 3 Date of toxicity assessment... Form is related to (0=baseline, 1= brachytherapy, 2= EBRT, 3= follow up)... Were there any toxicities during this time period? (0=no, 1=yes)... Were there any of these toxicities serious? (0=no, 1=yes)... If yes, date SAE was submitted... TOXICITIES: (Please use CTC AE Version 4) (drop down menu met graad in ecrf) Gastrointestinal disorders: Diarrhoea (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Faecal incontinence (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Flatulence (0=no, 1= grade 1, 2= grade 2)... Nausea (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Proctitis (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Rectal haemorrhage (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Rectal mucositis (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Rectal pain (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Rectal fistula (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Small bowel obstruction or ileus (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Vomiting (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Gastro-intestinal, other, (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Specify other gastro intestinal toxicity... Renal and urinary disorders: Cystitis, non infective (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Haematuria (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Urinary frequency (0=no, 1= grade 1, 2= grade 2)... Urinary incontinence (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Urinary urgency (0=no, 1= grade 1, 2= grade 2)... Urinary retention (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Urinary tract pain (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Renal and urinary, other, (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Specify other renal and urinary toxicity...
11 May 2017 Toxicity form Form 5, page 2 of 3 Infections: Bladder (0=no, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Infection, other, (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Specify other infection... Reproductive system disorders: Dyspareunia (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Vaginal discharge (0=no, 1= grade 1, 2= grade 2)... Vaginal dryness (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Vaginal fistula (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Vaginal haemorrhage (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Vaginal inflammation (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... Vaginal pain (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Vaginal stricture (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 5= grade 5)... General disorders: Fatigue (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Vascular disorders: Lymphedema (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Musculoskeletal and connective tissue disorders: Back pain (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Pain in extremity/hip (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Arthralgia (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Osteoporosis (0=no, 1= grade 1, 2= grade 2, 3= grade 3)... Injury, poisoning and procedural complications: Fracture (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)...
12 May 2017 Toxicity form Form 5, page 3 of 3 Any other major toxicities (for example, SAE toxicities that do not fall under any other category): Was any other major toxicity present, (0=no, 1= yes)... Specify this toxicity using CTC 4 terminology... Specify grade of this toxicity (0=no, 1= grade 1, 2= grade 2, 3= grade 3, 4= grade 4, 5= grade 5)... HEALTH CARE USE (only during follow-up): Admission to hospital for any of the above toxicities in the past 6 months? (0=no, yes) If yes, number of days?... Surgery for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, specify which operation... Date:.. Investigator s signature:.
13 May 2017 Follow up form Form 6, page 1 of 2 SURVIVAL STATUS: Date last known to be alive or date of death... Survival status (0=alive, 1=dead)... If dead, main cause... 1 = Endometrial carcinoma, disease progression (main cause: distant metastases) 2 = Endometrial carcinoma, disease progression (main cause: pelvic disease) 3 = Treatment complications (primary treatment), please specify... 4 = Intercurrent death, cardiovascular, please specify... 5 = Intercurrent death, second cancer, please specify... 6 = Intercurrent death, other, please specify... 7 = other or uncertain, please specify... PATIENT AND DISEASE STATUS: WHO performance Status (0-4)... Vaginal atrophy at pelvic exam (0 = no atrophy 1 = slight atrophic changes, 2 = moderate atrophy with teleangiectasia, 3 = marked atrophy with stenosis/shortening 4 = ulceration or necrosis)... Vagina (0=no tumour, 1= new recurrence, 2= complete remission after treatment of recurrence, 3= partial remission or stable disease after treatment of recurrences, 4= progression)... Pelvic region (0=no tumour, 1= new recurrence, 2= complete remission after treatment of recurrence, 3= partial remission or stable disease after treatment of recurrences, 4= progression)... Distant sites (0=no tumour, 1= new recurrence, 2= complete remission after treatment of recurrence, 3= partial remission or stable disease after treatment of recurrences, 4= progression)... HEALTH CARE USE (related to recurrences): Admission to hospital for any of the above events in the past 6 months? (0=no, yes)... If yes, number of days?... Surgery for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, specify which operation... Radiation therapy for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, specify type (1=external beam RT; 2= vaginal brachytherapy; 3=both)... Please specify... Chemotherapy for any of the above events in the past 6 months? (0=no, 1=yes)...
14 May 2017 Follow up form Form 6, page 2 of 2 If yes, please specify type and number of cycles... Hormonal therapy for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, please specify type... Any other intervention for any of above events in the past 6 months? (0=no, 1=yes)... If yes, please specify type... INVESTIGATIONS (ANNUALLY): Date of chest radiograph... Outcome (0=normal, 1=benign abnormalities, 2=suspect for metastases)... SECOND CANCER: Diagnosis of second cancer (0=no, 1=yes)... If yes, cancer type (1=Gastro intestinal, specify below, 2= breast, 3= other, specify below)... Specify type of second cancer... Date of diagnosis... Type of treatment (1=curative intent, 2= palliative intent, 3= no treatment)... If curative treatment, please specify... HEALTH CARE USE (related to second cancer): Admission to hospital for any of the above events in the past 6 months? (0=no, yes)... If yes, number of days?... Surgery for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, specify which operation... Radiation therapy for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, specify type (1=external beam RT; 2= vaginal brachytherapy; 3=both)... Please specify... Chemotherapy for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, please specify type and number of cycles... Hormonal therapy for any of the above events in the past 6 months? (0=no, 1=yes)... If yes, please specify type... Any other intervention for any of above events in the past 6 months? (0=no, 1=yes)... If yes, please specify type... Date:.. Investigator s signature:.
15 May 2016 Recurrence form Form 7, page 1 of 2 RECURRENCE: Vagina (0 = no tumor, 1 = recurrence proximal 1/3 vagina, 2 = recurrence mid 1/3 vagina, 3 = recurrence distal 1/3 vagina, 4 = multiple vaginal site(s), specify)... Specify multiple sites... Date of confirmation... Type of confirmation (1= histology, 2= cytology)... Pelvis (up to level L5-S1) (0 = no tumor, 1 = central recurrence, 2 = side wall, 3 = multiple)... Specify multiple sites... Date of confirmation... Type of confirmation (1= histology, 2= cytology, 3= CT or MRI scan, 4=PET/CT)... Abdominal or distant sites (0 = no tumor, 1 = metastases)... Site(s) of metastases... 1 = Malignant ascites 2 = Lower para-aortic lymph node metastases (between levels L3-4 and L5-S1) 3 = Upper para-aortic lymph node metastases (above level L3-4 or both upper and lower) 4 = Peritonitis carcinomatosis 5 = Liver 6 = Lung 7 = Bone 8 = other or combination, please specify... Date of confirmation... Type of confirmation (1= histology, 2= cytology, 3= CT or MRI scan, 4= PET/CT)... TREATMENT FOR RECURRENCE: Was treatment given (0=no, 1=yes, curative intent, 2= yes, palliative intent)... Start date of treatment... What type of treatment was given (1=chemotherapy, 2=hormonal therapy, 3=radiotherapy, 4=surgery, 5= targeted therapy, 6=other)... If a combination of treatment was given, please specify additional treatment...
16 May 2016 Recurrence form Form 7, page 2 of 2 If chemotherapy, please specify agents (1= carboplatin-paclitaxel, 2= doxorubicin-cisplatin, 3= paclitaxeldoxorubicin-cisplatin, 4=other, please specify)... Specify other chemotherapy regime... Number of cycles... If hormonal therapy, please specify agents (1= provera or megesterol acetate, 2= tamoxifen, 3= aromatase inhibitor) If targeted therapy or other, please specify type and agent(s)... If surgery, please specify type... If radiotherapy, please specify regime (1= EBRT to pelvic area +/- EBRT boost, 2= EBRT plus brachytherapy boost, 3= vaginal brachytherapy, 4=EBRT to pelvic and peri-aortic area +/- EBRT boost, 5=EBRT to periaortic area +/- EBRT boost, 6=other)... Specify other radiotherapy regime... Total dose EBRT (Gy).... Number of fractions... EBRT boost target (1= vaginal area, 2= pelvic nodes, 3= both, 4=peri-aortic, 5=other, please specify)... Specify other EBRT boost target area... Total dose vaginal brachytherapy (Gy).... Number of fractions... RESULT OF TREATMENT FOR RECURRENCE: Result of treatment for recurrence (1= CR, 2= PR, 3= stable disease, 4=progressive disease, 5=not yet evaluated)... Date of evaluation... Type of evaluation (1= CT or MRI scan, 2= PET/CT, 3=X-ray)... Specify additional treatment details... Date:.. Investigator s signature:.
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
Case Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
What is endometrial cancer?
Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women
Endometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
Adjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
Staging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates
J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs
Endometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
Cervical Cancer 3/25/2019. Abnormal vaginal bleeding
Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms
Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
Case Report Forms (CRF) Completion Guidelines
Page 1 of 6 PORTEC-3, CKTO 2006-04, CME P06.031 PORTEC-3 Version 22 sept 2006 Case Report Forms (CRF) Completion Guidelines List of forms Form.nr. Nr.of pages Title 1 2 Randomization checklist 2 3 On-study
New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
ARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
Cervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
Vaginal intraepithelial neoplasia
Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the
NAACCR Webinar Series /7/17
COLLECTING CANCER DATA: UTERUS 2017 2018 NAACCR WEBINAR SERIES Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
One of the commonest gynecological cancers,especially in white Americans.
Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in
ARRO Case: Early-stage Endometrial Cancer
ARRO Case: Early-stage Endometrial Cancer Ankit Modh, MD (PGY-4) Faculty Advisor: Mohamed A Elshaikh, MD Department of Radiation Oncology Henry Ford Cancer Institute Case Presentation 70 y/o African American
MRI in Cervix and Endometrial Cancer
28th Congress of the Hungarian Society of Radiologists RCR Session Budapest June 2016 MRI in Cervix and Endometrial Cancer DrSarah Swift St James s University Hospital Leeds, UK Objectives Cervix and endometrial
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with
ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป
ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป Brachytherapy การร กษาด วยร งส ระยะใกล Insertion การสอดใส แร Implantation การฝ งแร Surface application การวางแร physical benefit of brachytherapy - very high dose of radiation
Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru
Sarah Burton Lead Gynae Oncology Nurse Specialist Cancer Care Cymru Gynaecological Cancers Cervical Cancers Risk factors Presentation Early sexual activity Multiple sexual partners Smoking Human Papiloma
Janjira Petsuksiri, M.D
GYN malignancies Janjira Petsuksiri, M.D Outlines Cervical cancer Endometrial cancer Ovarian cancer Vaginal cancer Vulva cancer 2 CA Cervix Epidemiology - Second most common female cancer Risk factors
Index. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
GYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology
GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial
Gynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0)
Gynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0) ** VALID ON DATE OF PRINTING ONLY all guidelines available on the Strategic Clinical Network website : GMLSC SCN Date first published
The New ICRU/GEC ESTRO Report in Clinical Practice. Disclosures
The New ICRU/GEC ESTRO Report in Clinical Practice Christian Kirisits, MSc, PhD; Richard Pötter, MD Medical University of Vienna, Vienna, Austria On behalf of the Committee: B. Erickson, C. Haie Meder,
Guideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2
Radiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
Enterprise Interest None
Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf
MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA
2009 USCAP Gyn Pathology Evening Session Case #3 Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA rzaino@psu.edu Clinical history Middle aged woman with an exophytic mass of
C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
Endometrial cancer. Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology.
Endometrial cancer Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology dr.mate.szabolcs@gmail.com Epidemiology Developing countries Cervical cancer is the most common gyn. malignant tumor
Locally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
Jacqui Morgan March 6, 2019
Jacqui Morgan March 6, 2019 Case 1 25yo, G2P1 Here for WWE, no problems, healthy, needs refill on OCPs. Pap- Abnormal Glandular Cells-NOS Now What?? Case 1 Colposcopy What findings? Case 1 ECC Cervical
TOC NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence,
PET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
receive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
Quiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary
North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy
Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Guidelines for postoperative irradiation of cervical cancer Contents: 1. Treatment planning for EBRT. 2 2. Target definition for
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
https://patient.varian.com/sit es/default/files/videos/origin al/imrt.mp4 brachy- from Greek brakhys "short" Historically LDR has been used. Cs-137 at 0.4-0.8 Gy/h With optimally placed device, dose
Trimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
Uterus Malignancies /5/15
Collecting Cancer Data: Uterus 2014-2015 NAACCR Webinar Series February 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
Type I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53
Type I Excess estrogen Lynch Endometrioid adenocarcinoma PTEN Type II High grade More aggressive Serous, Clear Cell p53 Stage I IA IB Stage II Stage III IIIA IIIB IIIC IIIC1 IIIC2 Stage IV IVA IVB nodes
Post operative Radiotherapy in Carcinoma Endometrium - KMIO Experience (A Retrospective Study)
Post operative Radiotherapy in Carcinoma Endometrium - KMIO Experience (A Retrospective Study) Sridhar.P, M.D. 1, Sruthi.K, M.D. 2, Naveen.T, M.D. 3, Siddanna.R.P, M.D. 4 Department of Radiation Oncology,
17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122
Ovarian cancer: recognition and initial management Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
Newton Wellesley Hospital 2013
Newton Wellesley Hospital 20 Standard 4.6 Assessment and Evaluation of Treatment Planning Endometrial Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic
ENDOMETRIAL CANCER: A GUIDE FOR PATIENTS
ENDOMETRIAL CANCER: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by Reliable Cancer Therapies (RCT) as a service to patients,
Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
Radiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
Gynaecological Oncology Cases
Gynaecological Oncology Cases 1. Tamoxifen and the endometrium 2. Cancer and the older woman Dr Julie M Lamont Consultant Gynaecological Oncologist Epworth Freemasons Hospital 21 st April 2015 Mrs FS 66
Algorithms for management of Cervical cancer
Algithms f management of Cervical cancer Algithms f management of cervical cancer are based on existing protocols and guidelines within the ESGO comunity and prepared by ESGO Educational Committe as a
11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
X-Plain Ovarian Cancer Reference Summary
X-Plain Ovarian Cancer Reference Summary Introduction Ovarian cancer is fairly rare. Ovarian cancer usually occurs in women who are over 50 years old and it may sometimes be hereditary. This reference
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION
Torisel (temsirolimus)
Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/1/2017 POLICY A. INDICATIONS The indications below
Country Presentations of FNCA FY2007 Workshop on Radiation Oncology
Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Annex 3 Country presentations on CERVIX-III -China: Total Patients: 18, 8 alive: 1 with metastasis lung, another one metastasis to liver;
Definition of Synoptic Reporting
Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are
RECTUM/SIGMOID COLON/BOWEL,
EMBRACE Follow-up Patient ID: Day Month Year Physician (initials) RECTUM/SIGMOID COLON/BOWEL, morbidity scoring CTC v3.0 1. Diarrhea 1: Increase of
Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
Image guided brachytherapy in cervical cancer Clinical Aspects
Image guided brachytherapy in cervical cancer Clinical Aspects Richard Pötter MD Department of Radiation Oncology, Medical University of Vienna, Austria ICARO-2, IAEA, Vienna, June, 22, 2017 Outline Tumor
Mesonephric carcinoma of the uterine corpus: A report of two cases
ONCOLOGY LETTERS 11: 335-339, 2016 Mesonephric carcinoma of the uterine corpus: A report of two cases JIANGUO ZHAO 1,2, CAIYAN LIU 2, JI QI 2 and PENGPENG QU 2 1 Clinical College of Central Gynecology
ENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media
For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial
Rochester Minnesota Mayo Clinic
Are There Still Indications for Lymphadenectomy in Endometrial Cancer? A Mariani Mayo Clinic Rochester - MN USA Rochester Minnesota Mayo Clinic 1 Endometrial Cancer Lymphadenectomy Yes or No? Endometrial
Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center
Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center 50 yo healthy postmenopausal female with BMI = 35 with screening PAP smear = AGUS. What is the next step? (1) Colposcopy
Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.
Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying
NAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary
NAACCR 2011 2012 Webinar Series Collecting Cancer Data: Ovary Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
Guidelines for Assigning Summary Stage 2000
Guidelines for Assigning Summary Stage 2000 Mary Lewis, CTR National Program of Cancer Registries 2014 NCRA Annual Meeting May 17, 2014 National Center for Chronic Disease Prevention and Health Promotion
MRI for cervical and endometrial cancers. Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB
MRI for cervical and endometrial cancers Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB RCR 06(1) RCR 06(1) Technique Pelvic multiphased-array coil Fasting? Buscopan? ABDOMEN!!! Cx:+/- HR
Gynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1
What is Gynecologic Cancer Gynecologic Cancers Marge Ramsdell RN, MN, OCN Madigan Army Medical Center Any cancer that starts in a woman s reproductive organs Each GYN cancer is unique 5 main types Cervical
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE
UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE Case: Adenosarcoma with heterologous elements and stromal overgrowth o TAH, BSO, omentectomy, staging biopsies of cul-de-sac, bladder
Introduction to clinical Radiotherapy
Introduction to clinical Radiotherapy Sarah Brothwood Radiotherapy Practice Educator Rosemere Cancer Centre Sarah.brothwood@lthtr.nhs.uk 01772 522694 Radiotherapy We have been able to see and document
Endometrial cancer. Cathrine Holland
Endometrial cancer athrine Holland Abstract Endometrial cancers are the most common gynaecological malignancies in the UKwith approximately 4500 new cases occur each year and the incidence is rising. Increasingly
Prostate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 Final Pathology:
Abstracting Upper GI Cancer Incidence and Treatment Data Quiz 1 Multiple Primary and Histologies Case 1 A 74 year old male with a history of GERD presents complaining of dysphagia. An esophagogastroduodenoscopy
Gynecologic Malignancies. Kristen D Starbuck 4/20/18
Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial
29 Cancer of the Uterine Corpus
29 Cancer of the Uterine Corpus Robbert Soeters INTRODUCTION Malignancies affecting the uterine corpus are endometrial adenocarcinoma and uterine sarcomas. ENDOMETRIAL ADENOCARCINOMA Endometrial adenocarcinoma
Uterine sarcoma. Information for patients Gynaecology
Uterine sarcoma Information for patients Gynaecology page 2 of 12 This leaflet is intended to offer you support and information at a very difficult and stressful time in your life. To be told that you
Vagina. 1. Introduction. 1.1 General Information and Aetiology
Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.
The Role of Radiation in the Management of Gynecologic Cancers. Scott Glaser, MD
The Role of Radiation in the Management of Gynecologic Cancers Scott Glaser, MD Nothing to disclose DISCLOSURE Outline The role of radiation in: Endometrial Cancer Adjuvant Medically inoperable Cervical
Cervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford